global Actinic Keratosis Treatment market size is expected to be worth around US$ 9.18 billion by 2028, according to a new report by Vision Research Reports.
The global Actinic Keratosis Treatment market size was valued at US$ 6.10 billion in 2020 and is anticipated to grow at a CAGR of 4.10% during forecast period 2021 to 2028.
Growth Factors
The market is driven high prevalence of the disease, rapid technological advancements, and rise in consumer awareness.
Topical therapeutics generated the highest revenue among other therapeutic segments, in 2018. However, photodynamic therapy is anticipated to witness a healthy growth through the forecast period. Rising trend of photodynamic and combination therapies is expected to favorably drive the growth in near future.
North America led the actinic keratosis treatment market in 2020, driven by high prevalence of disease, presence of key manufacturers, and several awareness campigns initiated by public and provate organizations. North America is anticipated to maintain its leading position throughout the forecast period. Asia Pacific, on the other hand, is anticipated to witness the fastest growth, supported by a rising disposable income and favorable government initiatives.
Report Highlights
Topical products led the actinic keratosis therapies in 2020, driven by easy availability and deep market penetration. Topical treatments are used for targeting a wide area of visible and invisible lesions on the skin. Also called field therapy, topical treatments have a low risk of scarring.
Surgical procedures for actinic keratosis treatment is likely to lose market shares over the next few years due to alternative therapies that do not physically destruct skin tissues or cause permanent scars. Photodynamic therapy is swiftly gaining ground, marked by their increasing market absorption and significant commercial opportunities.
Hospitals end use segment led the market, in 2020. The growth is driven by ease of accessibility and availability to patients. The rise in healthcare infrastructure, especially in developing economies, is a key driver.
Homecare is anticipated to demonstrate a rapid growth over the forecast period, supported by high consumer awareness and self-care treatment options. Furthermore, increasing opportunities for caregivers and nurses for home healthcare services are a major propeller for actinic keratosis treatment market growth.
Photoenhancers are projected to witness a healthy growth over the next few years by virtue of strong commercial opportunities and relatively low competitive rivalry. NSAIDs and immune response modifiers are forecasted to maintain their market shares in the foreseeable future.
North America led the market in 2020, by contributing nearly 35.0% to the overall revenue share, driven by an increasing disease prevalence and proactive government initiatives. Local presence of key manufacturers as well as regulatory entities is anticipated to foster market growth in the near future.
Asia Pacific is estimated to expand at a lucrative CAGR over the forecast period. The high prevalence of the disease in southern areas, such as Australia and New Zealand, is the major regional growth driver. In addition, increasing disposable income and rise in consumer awareness contribute significantly to the rapid regional growth.
Key Players
Bausch Health Companies Inc.; LEO Pharma A/S; Almirall, S.A.; Biofrontera, Inc.; Nestlé S.A.; Sun Pharmaceutical Industries Ltd.; Novartis International AG; 3M Pharmaceuticals Inc.; Hill Dermaceuticals, Inc.; and Mylan N.V.
Market Segmentation
Therapy Outlook
Topical
Surgery
Photodynamic Therapy
Drug Class Outlook
Nucleoside Metabolic Inhibitors
NSAIDs
Immune Response Modifiers
Photoenhancers
Others
End use Outlook
Hospitals
Private Clinics
Homecare
Others
Regional Outlook
North America
U.S.
Canada
Europe
U.K.
Germany
Spain
France
Italy
Asia Pacific
Japan
China
India
South Korea
Australia
Latin America
Brazil
Mexico
Argentina
Middle East & Africa
South Africa
Saudi Arabia
UAE
The Actinic Keratosis Treatment market research report covers definition, classification, product classification, product application, development trend, product technology, competitive landscape, industrial chain structure, industry overview, national policy and planning analysis of the industry, the latest dynamic analysis, etc., and also includes major. The study includes drivers and restraints of the global market. It covers the impact of these drivers and restraints on the demand during the forecast period. The report also highlights opportunities in the market at the global level.
The report provides size (in terms of volume and value) of Actinic Keratosis Treatment market for the base year 2020 and the forecast between 2021 and 2028. Market numbers have been estimated based on form and application. Market size and forecast for each application segment have been provided for the global and regional market.
This report focuses on the global Actinic Keratosis Treatment market status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Actinic Keratosis Treatment market development in United States, Europe and China.
It is pertinent to consider that in a volatile global economy, we haven’t just conducted Actinic Keratosis Treatment market forecasts in terms of CAGR, but also studied the market based on key parameters, including Year-on-Year (Y-o-Y) growth, to comprehend the certainty of the market and to find and present the lucrative opportunities in market.
In terms of production side, this report researches the Actinic Keratosis Treatment capacity, production, value, ex-factory price, growth rate, market share for major manufacturers, regions (or countries) and type.
In terms of consumption side, this report focuses on the consumption of Actinic Keratosis Treatment by regions (countries) and application.
Buyers of the report will have access to verified market figures, including global market size in terms of revenue and volume. As part of production analysis, the authors of the report have provided reliable estimations and calculations for global revenue and volume by Type segment of the global Actinic Keratosis Treatment market. These figures have been provided in terms of both revenue and volume for the period 2017 to 2028. Additionally, the report provides accurate figures for production by region in terms of revenue as well as volume for the same period. The report also includes production capacity statistics for the same period.
With regard to production bases and technologies, the research in this report covers the production time, base distribution, technical parameters, research and development trends, technology sources, and sources of raw materials of major Actinic Keratosis Treatment market companies.
Regarding the analysis of the industry chain, the research of this report covers the raw materials and equipment of Actinic Keratosis Treatment market upstream, downstream customers, marketing channels, industry development trends and investment strategy recommendations. The more specific analysis also includes the main application areas of market and consumption, major regions and Consumption, major Chinese producers, distributors, raw material suppliers, equipment providers and their contact information, industry chain relationship analysis.
The research in this report also includes product parameters, production process, cost structure, and data information classified by region, technology and application. Finally, the paper model new project SWOT analysis and investment feasibility study of the case model.
Overall, this is an in-depth research report specifically for the Actinic Keratosis Treatment industry. The research center uses an objective and fair way to conduct an in-depth analysis of the development trend of the industry, providing support and evidence for customer competition analysis, development planning, and investment decision-making. In the course of operation, the project has received support and assistance from technicians and marketing personnel in various links of the industry chain.
The Actinic Keratosis Treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related to Actinic Keratosis Treatment market.
Prominent players in the market are predicted to face tough competition from the new entrants. However, some of the key players are targeting to acquire the startup companies in order to maintain their dominance in the global market. For a detailed analysis of key companies, their strengths, weaknesses, threats, and opportunities are measured in the report by using industry-standard tools such as the SWOT analysis. Regional coverage of key companies is covered in the report to measure their dominance. Key manufacturers of Actinic Keratosis Treatment market are focusing on introducing new products to meet the needs of the patrons. The feasibility of new products is also measured by using industry-standard tools.
Key companies are increasing their investments in research and development activities for the discovery of new products. There has also been a rise in the government funding for the introduction of new Actinic Keratosis Treatment market. These factors have benefited the growth of the global market for Actinic Keratosis Treatment. Going forward, key companies are predicted to benefit from the new product launches and the adoption of technological advancements. Technical advancements have benefited many industries and the global industry is not an exception.
New product launches and the expansion of already existing business are predicted to benefit the key players in maintaining their dominance in the global market for Actinic Keratosis Treatment. The global market is segmented on the basis of region, application, en-users and product type. Based on region, the market is divided into North America, Europe, Asia-Pacific, Latin America and Middle East and Africa (MEA).
In this study, the years considered to estimate the market size of Actinic Keratosis Treatment are as follows:
Reasons to Purchase this Report:
- Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects
- Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
- Market value USD Million and volume Units Million data for each segment and sub-segment
- Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
- Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players
Research Methodology:
In-depth interviews and discussions were conducted with several key market participants and opinion leaders to compile the research report.
This research study involved the extensive usage of both primary and secondary data sources. The research process involved the study of various factors affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry, and market risks, opportunities, market barriers and challenges. The following illustrative figure shows the market research methodology applied in this report.
Market Size Estimation
Top-down and bottom-up approaches are used to estimate and validate the global market size for company, regional division, product type and application (end users).
The market estimations in this report are based on the selling price (excluding any discounts provided by the manufacturer, distributor, wholesaler or traders). Market share analysis, assigned to each of the segments and regions are achieved through product utilization rate and average selling price.
Major manufacturers & their revenues, percentage splits, market shares, growth rates and breakdowns of the product markets are determined through secondary sources and verified through the primary sources.
All possible factors that influence the markets included in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data. The market size for top-level markets and sub-segments is normalized, and the effect of inflation, economic downturns, and regulatory & policy changes or others factors are accounted for in the market forecast. This data is combined and added with detailed inputs and analysis from Vision Research Reports and presented in this report.
Market Breakdown and Data Triangulation
After complete market engineering with calculations for market statistics; market size estimations; market forecasting; market breakdown; and data triangulation. Extensive primary research was conducted to gather information and verify and validate the critical numbers arrived at. In the complete market engineering process, both top-down and bottom-up approaches were extensively used, along with several data triangulation methods, to perform market estimation and market forecasting for the overall market segments and sub-segments listed in this report.
Secondary Sources
Secondary Sources occupies approximately 25% of data sources, such as press releases, annual reports, Non-Profit organizations, industry associations, governmental agencies and customs data, and so on. This research study includes secondary sources; directories; databases such as Bloomberg Business, Wind Info, Hoovers, Factiva (Dow Jones & Company), TRADING ECONOMICS, and avention; Investing News Network; statista; Federal Reserve Economic Data; annual reports; investor presentations; and SEC filings of companies.
Primary Sources
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include product manufacturers (and their competitors), opinion leaders, industry experts, research institutions, distributors, dealer and traders, as well as the raw materials suppliers and producers, etc.
The primary sources from the demand side include industry experts such as business leaders, marketing and sales directors, technology and innovation directors, supply chain executive, end users (product buyers), and related key executives from various key companies and organizations operating in the global market.
The study objectives of this report are:
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. Market Dynamics Analysis and Trends
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
Chapter 6. Competitive Landscape
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
Chapter 7. Global Actinic Keratosis Treatment Market, By Therapy
7.1. Actinic Keratosis Treatment Market, By Therapy, 2021-2028
7.1.1. Topical
7.1.1.1. Market Revenue and Forecast (2016-2028)
7.1.2. Surgery
7.1.2.1. Market Revenue and Forecast (2016-2028)
7.1.3. Photodynamic Therapy
7.1.3.1. Market Revenue and Forecast (2016-2028)
Chapter 8. Global Actinic Keratosis Treatment Market, By Drug Class
8.1. Actinic Keratosis Treatment Market, By Drug Class, 2021-2028
8.1.1. Nucleoside Metabolic Inhibitors
8.1.1.1. Market Revenue and Forecast (2016-2028)
8.1.2. NSAIDs
8.1.2.1. Market Revenue and Forecast (2016-2028)
8.1.3. Immune Response Modifiers
8.1.3.1. Market Revenue and Forecast (2016-2028)
8.1.4. Photoenhancers
8.1.4.1. Market Revenue and Forecast (2016-2028)
Chapter 9. Global Actinic Keratosis Treatment Market, By End User
9.1. Actinic Keratosis Treatment Market, by End User, 2021-2028
9.1.1. Hospitals
9.1.1.1. Market Revenue and Forecast (2016-2028)
9.1.2. Private Clinics
9.1.2.1. Market Revenue and Forecast (2016-2028)
9.1.3. Homecare
9.1.3.1. Market Revenue and Forecast (2016-2028)
9.1.4. Others
9.1.4.1. Market Revenue and Forecast (2016-2028)
Chapter 10. Global Actinic Keratosis Treatment Market, Regional Estimates and Trend Forecast
10.1. North America
10.1.1. Market Revenue and Forecast, By Therapy (2016-2028)
10.1.2. Market Revenue and Forecast, By Drug Class (2016-2028)
10.1.3. Market Revenue and Forecast, by End User (2016-2028)
10.1.4. U.S.
10.1.4.1. Market Revenue and Forecast, By Therapy (2016-2028)
10.1.4.2. Market Revenue and Forecast, By Drug Class (2016-2028)
10.1.4.3. Market Revenue and Forecast, by End User (2016-2028)
10.1.5. Rest of North America
10.1.5.1. Market Revenue and Forecast, By Therapy (2016-2028)
10.1.5.2. Market Revenue and Forecast, By Drug Class (2016-2028)
10.1.5.3. Market Revenue and Forecast, by End User (2016-2028)
10.2. Europe
10.2.1. Market Revenue and Forecast, By Therapy (2016-2028)
10.2.2. Market Revenue and Forecast, By Drug Class (2016-2028)
10.2.3. Market Revenue and Forecast, by End User (2016-2028)
10.2.4. UK
10.2.4.1. Market Revenue and Forecast, By Therapy (2016-2028)
10.2.4.2. Market Revenue and Forecast, By Drug Class (2016-2028)
10.2.4.3. Market Revenue and Forecast, by End User (2016-2028)
10.2.5. Germany
10.2.5.1. Market Revenue and Forecast, By Therapy (2016-2028)
10.2.5.2. Market Revenue and Forecast, By Drug Class (2016-2028)
10.2.5.3. Market Revenue and Forecast, by End User (2016-2028)
10.2.6. France
10.2.6.1. Market Revenue and Forecast, By Therapy (2016-2028)
10.2.6.2. Market Revenue and Forecast, By Drug Class (2016-2028)
10.2.6.3. Market Revenue and Forecast, by End User (2016-2028)
10.2.7. Rest of Europe
10.2.7.1. Market Revenue and Forecast, By Therapy (2016-2028)
10.2.7.2. Market Revenue and Forecast, By Drug Class (2016-2028)
10.2.7.3. Market Revenue and Forecast, by End User (2016-2028)
10.3. APAC
10.3.1. Market Revenue and Forecast, By Therapy (2016-2028)
10.3.2. Market Revenue and Forecast, By Drug Class (2016-2028)
10.3.3. Market Revenue and Forecast, by End User (2016-2028)
10.3.4. India
10.3.4.1. Market Revenue and Forecast, By Therapy (2016-2028)
10.3.4.2. Market Revenue and Forecast, By Drug Class (2016-2028)
10.3.4.3. Market Revenue and Forecast, by End User (2016-2028)
10.3.5. China
10.3.5.1. Market Revenue and Forecast, By Therapy (2016-2028)
10.3.5.2. Market Revenue and Forecast, By Drug Class (2016-2028)
10.3.5.3. Market Revenue and Forecast, by End User (2016-2028)
10.3.6. Japan
10.3.6.1. Market Revenue and Forecast, By Therapy (2016-2028)
10.3.6.2. Market Revenue and Forecast, By Drug Class (2016-2028)
10.3.6.3. Market Revenue and Forecast, by End User (2016-2028)
10.3.7. Rest of APAC
10.3.7.1. Market Revenue and Forecast, By Therapy (2016-2028)
10.3.7.2. Market Revenue and Forecast, By Drug Class (2016-2028)
10.3.7.3. Market Revenue and Forecast, by End User (2016-2028)
10.4. MEA
10.4.1. Market Revenue and Forecast, By Therapy (2016-2028)
10.4.2. Market Revenue and Forecast, By Drug Class (2016-2028)
10.4.3. Market Revenue and Forecast, by End User (2016-2028)
10.4.4. GCC
10.4.4.1. Market Revenue and Forecast, By Therapy (2016-2028)
10.4.4.2. Market Revenue and Forecast, By Drug Class (2016-2028)
10.4.4.3. Market Revenue and Forecast, by End User (2016-2028)
10.4.5. North Africa
10.4.5.1. Market Revenue and Forecast, By Therapy (2016-2028)
10.4.5.2. Market Revenue and Forecast, By Drug Class (2016-2028)
10.4.5.3. Market Revenue and Forecast, by End User (2016-2028)
10.4.6. South Africa
10.4.6.1. Market Revenue and Forecast, By Therapy (2016-2028)
10.4.6.2. Market Revenue and Forecast, By Drug Class (2016-2028)
10.4.6.3. Market Revenue and Forecast, by End User (2016-2028)
10.4.7. Rest of MEA
10.4.7.1. Market Revenue and Forecast, By Therapy (2016-2028)
10.4.7.2. Market Revenue and Forecast, By Drug Class (2016-2028)
10.4.7.3. Market Revenue and Forecast, by End User (2016-2028)
10.5. Latin America
10.5.1. Market Revenue and Forecast, By Therapy (2016-2028)
10.5.2. Market Revenue and Forecast, By Drug Class (2016-2028)
10.5.3. Market Revenue and Forecast, by End User (2016-2028)
10.5.4. Brazil
10.5.4.1. Market Revenue and Forecast, By Therapy (2016-2028)
10.5.4.2. Market Revenue and Forecast, By Drug Class (2016-2028)
10.5.4.3. Market Revenue and Forecast, by End User (2016-2028)
10.5.5. Rest of LATAM
10.5.5.1. Market Revenue and Forecast, By Therapy (2016-2028)
10.5.5.2. Market Revenue and Forecast, By Drug Class (2016-2028)
10.5.5.3. Market Revenue and Forecast, by End User (2016-2028)
Chapter 11. Company Profiles
11.1. Bausch Health Companies Inc.
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. LEO Pharma A/S
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Almirall, S.A.
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Biofrontera, Inc.
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. Nestlé S.A.
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Sun Pharmaceutical Industries Ltd.
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Novartis International AG
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. 3M Pharmaceuticals Inc.
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Hill Dermaceuticals, Inc.
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. Mylan N.V.
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
Chapter 12. Research Methodology
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
Chapter 13. Appendix
13.1. About Us
Glossary of Terms